Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ARGATROBAN IN 0.9% SODIUM CHLORIDE vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Direct thrombin inhibitor that reversibly binds to the active site of thrombin, inhibiting fibrin formation, activation of coagulation factors V, VIII, and XIII, and platelet aggregation.
Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.
Prophylaxis or treatment of thrombosis in patients with heparin-induced thrombocytopenia (HIT),Patients with or at risk of HIT undergoing percutaneous coronary intervention (PCI)
Treatment of acute bronchospasm in asthma and COPD,Reversal of dipyridamole-induced adverse effects during stress testing,Apnea of prematurity (off-label),Status asthmaticus (off-label)
Continuous IV infusion: 2 mcg/kg/min, adjusted to maintain a PTT 1.5-3 times baseline. Maximum initial infusion rate is 10 mcg/kg/min.
Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.
Terminal elimination half-life is 39–51 minutes in healthy subjects; prolonged to 181–269 minutes in patients with hepatic impairment. Clinical context: Short half-life allows rapid reversal of anticoagulation upon discontinuation.
Terminal elimination half-life is 6-12 hours in adults, 1-5 hours in children (due to faster clearance), 20-30 hours in premature neonates, and 10-15 hours in patients with hepatic cirrhosis or heart failure. Clinical context: dosing interval adjustment required based on half-life; prolonged half-life in hepatic impairment or cardiac decompensation increases risk of toxicity.
Primarily hepatic metabolism via hydroxylation and aromatization of the tetrahydrothiophene moiety; minimal cytochrome P450 involvement. Approximately 25% of the dose is excreted unchanged in urine.
Hepatic via cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2E1); saturable kinetics; extensive first-pass metabolism.
Primarily hepatic (biliary) excretion: approximately 65% eliminated via bile into feces; renal excretion accounts for about 22% as unchanged drug and metabolites.
Renal excretion of unchanged theophylline (10-20%) and metabolites (80-90%). In neonates, renal excretion of unchanged drug is higher (up to 50%). Biliary/fecal excretion is negligible.
Approximately 54% bound to human serum albumin and alpha-1-acid glycoprotein.
Approximately 40% bound to plasma proteins, mainly albumin. In neonates, preterm infants, and patients with hepatic cirrhosis, protein binding is reduced (free fraction increases). Binding is also saturable at high theophylline concentrations.
0.2–0.3 L/kg; predominantly confined to extracellular fluid, indicating limited tissue distribution.
Volume of distribution is approximately 0.45 L/kg (range 0.3-0.7 L/kg) in adults. In neonates, Vd is larger (~0.6-0.8 L/kg). Clinical meaning: Vd indicates extensive distribution into body water; loading doses are calculated using Vd (e.g., 1 mg/kg raises serum concentration by ~2 mcg/m L).
Intravenous only: 100% bioavailability by IV route. Not absorbed orally.
Oral immediate-release: 100% (well absorbed). Rectal: 80-100% (absorption may be erratic). IV: 100%. No significant first-pass metabolism.
No dose adjustment required for renal impairment, including end-stage renal disease (ESRD) on hemodialysis.
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce infusion rate by 50%.
For moderate hepatic impairment (Child-Pugh B): initial infusion rate 0.5 mcg/kg/min; adjust a PTT accordingly. For severe hepatic impairment (Child-Pugh C): initial infusion rate 0.25-0.5 mcg/kg/min; use lower end of range. Titrate carefully.
Child-Pugh Class A: reduce dose by 25%; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
Not approved for pediatric use; limited data available. In clinical studies for HIT, initial infusion rate 0.5-2 mcg/kg/min adjusted to a PTT.
Loading dose: 5-6 mg/kg IV over 20-30 minutes; continuous infusion: 0.5-0.7 mg/kg/hour (age-dependent, with lower doses for younger children).
No specific dose adjustment required; consider increased sensitivity and monitor a PTT closely.
Elderly patients may have reduced clearance; consider starting at the lower end of dosing range (e.g., 0.3-0.5 mg/kg/hour) and titrate based on serum levels.
Risk of bleeding including intracranial hemorrhage. Do not use in patients with active major bleeding or conditions with high risk of bleeding.
Theophylline toxicity is dose-related and can be fatal; monitor serum theophylline levels closely; use with caution in patients with risk factors for reduced clearance (e.g., hepatic impairment, heart failure, elderly).
Bleeding risk: Increased risk of major bleeding, especially in patients with renal impairment, hepatic impairment, or those receiving antiplatelet agents or thrombolytics.,Hepatic impairment: Use with caution in patients with hepatic disease as metabolism may be affected.,Renal impairment: Dose adjustment recommended for patients with moderate to severe renal impairment (Cr Cl <30 m L/min).,Hypersensitivity reactions: Reported, including anaphylaxis.,Concomitant use with anticoagulants, antiplatelets, or thrombolytics increases bleeding risk.
Narrow therapeutic index; severe toxicity can occur at levels >20 mcg/m L,Seizures and arrhythmias may occur without preceding symptoms,Variable clearance due to drug interactions, disease states, age, and smoking,Use with caution in peptic ulcer disease, seizure disorders, hyperthyroidism, and cardiac disease
Active major bleeding,History of hypersensitivity to argatroban,Caution in patients with intracranial hemorrhage, gastrointestinal bleeding, or recent surgery
Hypersensitivity to aminophylline or any component,Hypersensitivity to theophylline or ethylenediamine,Cardiac arrhythmias requiring immediate therapy (relative)
No specific food interactions known. However, avoid excessive alcohol consumption as it may increase bleeding risk.
Avoid high-dose caffeine (coffee, tea, energy drinks, chocolate) as it may increase risk of side effects like nausea, anxiety, and tachycardia. Charcoal-broiled foods and a high-protein diet may increase theophylline clearance. Consistent dietary intake is recommended.
FDA Pregnancy Category B. Animal studies at up to 5 times human AUC showed no fetal harm. No adequate human studies; risk cannot be excluded. Use only if clearly needed. First trimester: theoretical risk due to anticoagulation. Second/Third trimesters: increased risk of bleeding, placental abruption, preterm labor.
First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high maternal doses; may cause transient neonatal tachycardia with chronic use. No documented teratogenicity.
No data on argatroban in human milk; M/P ratio unknown. Consider risk of bleeding in infant. Use only if maternal benefit outweighs potential risk; avoid breastfeeding for 5 half-lives (2-3 hours) after last dose.
Aminophylline/theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant exposure is low (about 1-10% of maternal dose). Irritability and insomnia reported rarely. Use with caution, monitor infant for signs of theophylline toxicity.
No standard dose adjustment required; titrate based on a PTT. Pregnancy may increase volume of distribution and clearance; monitor a PTT closely. Start with 2 mcg/kg/min IV; adjust to a PTT 1.5-3x control. Hepatic impairment requires dose reduction.
Pregnancy decreases theophylline clearance by approximately 20-30% during third trimester. Dosing adjustments may be required: monitor serum levels and adjust dose to maintain therapeutic levels. Postpartum clearance returns rapidly, requiring downward dose adjustment.
Argatroban is a direct thrombin inhibitor used for heparin-induced thrombocytopenia (HIT). Monitor a PTT closely, target 1.5-3 times baseline. No reversal agent available; half-life ~40-50 min. Dose adjustment needed for hepatic impairment. Do not mix with other drugs in IV line. Use with caution in patients with bleeding risk.
Aminophylline is a bronchodilator that releases theophylline. Monitor serum theophylline levels (therapeutic range 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease, seizure disorders, or hypersensitivity to xanthines. Caution in hepatic impairment, heart failure, and elderly due to reduced clearance. Drug interactions with cimetidine, ciprofloxacin, and macrolides increase theophylline levels.
Argatroban prevents blood clots; you will have regular blood tests to monitor its effect.,Report any unusual bleeding, bruising, or dark stools immediately.,Avoid aspirin, NSAIDs, and other blood thinners unless prescribed by your doctor.,Tell all healthcare providers you are on argatroban before any procedure or surgery.,Do not stop or skip doses without consulting your doctor.
Do not exceed prescribed dose. Take exactly as directed.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, palpitations, or seizures.,Do not crush or chew extended-release forms; take with food if gastric upset occurs.,Do not stop abruptly without consulting your healthcare provider.
"Deferasirox, an oral iron chelator, reduces the serum concentration of argatroban, a direct thrombin inhibitor, likely through induction of hepatic metabolism. This interaction may lead to subtherapeutic anticoagulation, increasing the risk of thrombotic events such as deep vein thrombosis or pulmonary embolism. Clinicians should monitor anticoagulant effect closely and adjust argatroban dose accordingly."
"Hydroxyprogesterone caproate, a progestogen used to reduce preterm birth risk, may induce hepatic CYP450 enzymes, potentially increasing the clearance of argatroban, a direct thrombin inhibitor. This interaction could reduce argatroban's anticoagulant effect, increasing the risk of thromboembolic events in patients requiring anticoagulation. Clinical outcomes may include subtherapeutic anticoagulation and failure to prevent or treat thrombosis."
"Gestodene, a progestin component of combined oral contraceptives, induces hepatic CYP450 enzymes, including CYP3A4 and CYP2C9, which are responsible for the metabolism of argatroban, a direct thrombin inhibitor. This induction accelerates argatroban clearance, reducing its plasma concentration and anticoagulant effect, potentially leading to subtherapeutic anticoagulation and increased risk of thromboembolic events. Clinically, this interaction may result in decreased efficacy of argatroban during concurrent use with gestodene-containing contraceptives."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ARGATROBAN IN 0.9% SODIUM CHLORIDE vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, answered by our medical review team.
ARGATROBAN IN 0.9% SODIUM CHLORIDE is a Electrolyte that works by Direct thrombin inhibitor that reversibly binds to the active site of thrombin, inhibiting fibrin formation, activation of coagulation factors V, VIII, and XIII, and platelet aggregation.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ARGATROBAN IN 0.9% SODIUM CHLORIDE and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ARGATROBAN IN 0.9% SODIUM CHLORIDE is: Continuous IV infusion: 2 mcg/kg/min, adjusted to maintain a PTT 1.5-3 times baseline. Maximum initial infusion rate is 10 mcg/kg/min.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is: Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ARGATROBAN IN 0.9% SODIUM CHLORIDE and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ARGATROBAN IN 0.9% SODIUM CHLORIDE is classified as Category A/B. FDA Pregnancy Category B. Animal studies at up to 5 times human AUC showed no fetal harm. No adequate human studies; risk cannot be excluded. Use only if clearly needed. First trim. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is classified as Category A/B. First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.